文献速递乳腺癌

乳腺断层合成与数字乳腺X线摄影在有乳腺癌家族史女性中的筛查比较

Tomosynthesis vs Digital Mammography Screening in Women with a Family History of Breast Cancer.
PubMed 文献 · JAMA Oncol · 2025-01-01

这项比较队列研究纳入有乳腺癌家族史的成年女性,2011至2018年间接受数字乳腺断层合成(DBT)或数字乳腺X线摄影(DM)筛查,比较筛查性能。DBT较DM降低召回率并提高特异度,在有一名一级亲属和乳房散在纤维腺体密度的女性中尤为明显,在极度致密乳房中降低晚期癌率。

要点

  • DBT较DM总体召回率绝对风险差为-1.51%,特异度绝对风险差为1.56%。
  • 有一名一级亲属者DBT较DM召回率绝对风险差-1.72%,特异度绝对风险差1.75%。
  • 极度致密乳房中DBT较DM晚期癌率绝对风险差为每1000次检查-0.61。

核心结论

  • 在有乳腺癌家族史女性中,DBT筛查较DM降低召回率并提高特异度,在有一名一级亲属和散在纤维腺体密度者中尤为明显,在极度致密乳房中降低晚期癌率。

研究设计与样本

  • 比较队列研究,纳入乳腺癌症监测联盟附属影像机构中2011至2018年接受DBT或DM筛查的18岁及以上自报有乳腺癌家族史成年女性,随访1年乳腺癌发生,数据分析于2023年11月至2024年8月进行。
  • 样本共208945名女性、502357次筛查检查,其中DBT组121698次、DM组380561次检查;DBT组中位年龄58(IQR 50-66)岁,DM组57(IQR 49-66)岁。

主要发现

  • 总体队列中DBT较DM召回率绝对风险差为-1.51%(95%CI -2.42%至-0.59%),特异度绝对风险差为1.56%(95%CI 0.65%至2.46%)。
  • 有一名一级亲属者中DBT较DM召回率绝对风险差为-1.72%(95%CI -2.70%至-0.74%),特异度绝对风险差为1.75%(95%CI 0.81%至2.69%)。
  • 仅有二级亲属者中DBT较DM活检率绝对风险差为0.39%(95%CI 0.18%至0.61%)。
  • 几乎完全脂肪型乳房中DBT较DM原位导管癌检出率绝对风险差为每1000次检查-0.71(95%CI -1.03至-0.38);散在纤维腺体密度者中召回率绝对风险差-1.90%(95%CI -2.88%至-0.92%),特异度绝对风险差1.93%(95%CI 0.97%至2.89%)。
  • 不均匀致密乳房中DBT较DM召回阳性预测值绝对风险差为1.75%(95%CI 0.84%至2.67%);极度致密乳房中活检率绝对风险差0.48%(95%CI 0.16%至0.80%),晚期癌率绝对风险差每1000次检查-0.61(95%CI -1.02至-0.20)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Evidence on screening outcomes with digital breast tomosynthesis (DBT) vs digital mammography (DM) in women with a family history of breast cancer is limited. OBJECTIVE: To compare the performance of DBT and DM screening in women with a family history of breast cancer overall and subdivided by breast cancer family history category, breast density, age group, screening interval, and screening round, and to describe characteristics of cancers detected on screening vs interval cancers. DESIGN, SETTING, AND PARTICIPANTS: In this comparative cohort study at imaging facilities affiliated with the Breast Cancer Surveillance Consortium, adult women 18 years and older with a self-reported family history of breast cancer who underwent DBT or DM from 2011 to 2018 were included, with a 1-year follow-up for breast carcinoma. Data analysis was performed between November 2023 and August 2024. EXPOSURES: DBT or DM. MAIN OUTCOMES AND MEASURES: The main outcomes were absolute risk difference (ARD) between DBT and DM for recall rate, cancer detection rate, interval cancer rate, advanced cancer rate, biopsy rate, positive predictive values, sensitivity, and specificity, with inverse probability of treatment weighting. RESULTS: A total of 208 945 women with a family history of breast cancer undergoing 502 357 screening examinations were included in the sample. Median (IQR) age was 58 (50-66) and 57 (49-66) years for the DBT and DM groups, respectively. Adjusted ARDs (DBT vs DM) were significant for recall rate (-1.51%; 95% CI, -2.42% to -0.59%) and specificity (1.56%; 95% CI, 0.65%-2.46%) in the overall cohort of 121 698 DBT and 380 561 DM examinations and among women with 1 first-degree relative (recall rate ARD, -1.72%; 95% CI, -2.70% to -0.74%; specificity ARD, 1.75%; 95% CI, 0.81%-2.69%). Among those with only second-degree relatives, the biopsy rate for DBT was significantly higher (ARD, 0.39%; 95% CI, 0.18%-0.61%). Significant ARDs were observed for the ductal carcinoma in situ detection rate (-0.71 per 1000 examinations; 95% CI, -1.03 to -0.38 per 1000 examinations) in women with almost entirely fatty breasts; recall rate (-1.90%; 95% CI, -2.88% to -0.92%) and specificity (1.93%; 95% CI, 0.97%-2.89%) in women with scattered fibroglandular densities. Significant ARDs were also observed for the positive predictive value for recall (1.75%; 95% CI, 0.84%-2.67%) in heterogeneously dense breasts, as well as the biopsy rate (0.48%; 95% CI, 0.16%-0.80%) and advanced cancer rate (-0.61 per 1000 examinations; 95% CI, -1.02 to -0.20 per 1000 examinations) in extremely dense breasts. DBT screening had a higher proportion than DM of screen-detected early-stage, invasive cancers with favorable prognostic characteristics. CONCLUSIONS AND RELEVANCE: In this cohort study of women with a family history of breast cancer, DBT screening reduced recall rates and increased specificity compared to DM, particularly in women with 1 first-degree relative with breast cancer and those with scattered fibroglandular breast density, and reduced advanced cancer rates in women with extremely dense breasts.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Li T, Su YR, Lee JM, et al. Tomosynthesis vs Digital Mammography Screening in Women with a Family History of Breast Cancer. JAMA Oncol. 2025. PMID: 40402477. doi:10.1001/jamaoncol.2025.1209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。